Name (Synonyms) | Correlation | |
---|---|---|
drug1513 | JNJ-66525433 Wiki | 1.00 |
drug3011 | Unfractionated heparin nebulized Wiki | 1.00 |
drug3504 | unfractionated Heparin Wiki | 0.71 |
drug1004 | Enoxaparin Wiki | 0.29 |
drug2122 | Placebo Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D014456 | Ulcer NIH | 0.41 |
D003092 | Colitis NIH | 0.41 |
D003093 | Colitis, Ulcerative NIH | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0002583 | Colitis HPO | 0.41 |
HP:0100279 | Ulcerative colitis HPO | 0.41 |
There is one clinical trial.
Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and increased mortality. This is adaptive clinical trial to compare effectiveness and safety of four therapeutic strategies in hospital mortality in patients with COVID-19: standard prophylaxis, therapeutic dose anticoagulation, inhaled UFH associated with standard prophylaxis and ASA associated with standard prophylaxis.
Description: Number of COVID-19 positive patients who are alive within 30 days of symptoms onset
Measure: Hospital discharge - alive / death Time: 30 daysDescription: Comparison of length of mechanical ventilation free days between each treatment arm
Measure: Length of mechanical ventilation free days Time: 30 daysDescription: Comparison of length of renal replacement therapy free days between each treatment arm
Measure: Length of renal replacement therapy free days Time: 30 daysDescription: Comparison of number of thrombosis events between each treatment arm.
Measure: Number of documented venous thromboembolism or arterial thrombosis Time: 3 months